[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100657997":3},{"organization":4,"outcomesModule":7,"designInfo":28,"detailedDescription":11,"studyPopulation":31,"armGroups":32,"interventions":38,"overallOfficials":11,"centralContacts":44,"locations":11,"responsibleParty":50,"collaborators":11,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":54,"sex":60,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":11,"studyType":66,"phases":11,"briefSummary":67,"conditions":68,"keywords":70,"overallStatus":73,"whyStopped":11,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":11},{"fullName":5,"class":6},"Second Affiliated Hospital, Zhejiang University, School of Medicine","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Percentage change from baseline in NT-proBNP and\u002For absolute change from baseline in KCCQ-CSS",null,"From enrollment to the end of treatment at 24 months",[14,16,18,20,22,24,26],{"measure":15,"description":11,"timeFrame":12},"Absolute change from baseline in NT-proBNP",{"measure":17,"description":11,"timeFrame":12},"Percentage change from baseline in TnT\u002FTnI",{"measure":19,"description":11,"timeFrame":12},"Absolute change from baseline in TnT\u002FTnI",{"measure":21,"description":11,"timeFrame":12},"Absolute change from baseline in maximal wall thickness (MWT)",{"measure":23,"description":11,"timeFrame":12},"Absolute change from baseline in E\u002Fe'",{"measure":25,"description":11,"timeFrame":12},"Absolute change from baseline in left ventricular end-diastolic volume index (LVEDdi)",{"measure":27,"description":11,"timeFrame":12},"Proportion of patients with improvement of ≥1 NYHA functional class",{"allocation":11,"interventionModel":11,"interventionModelDescription":11,"primaryPurpose":11,"observationalModel":29,"timePerspective":30,"maskingInfo":11},"COHORT","PROSPECTIVE","Patients with symptomatic non-obstructive hypertrophic cardiomyopathy",[33],{"label":34,"type":11,"description":35,"interventionNames":36},"Aficamten group","Patients with non-obstructive hypertrophic cardiomyopathy (nHCM) receiving aficamten therapy",[37],"Drug: receiving aficamten",[39],{"type":40,"name":41,"description":42,"armGroupLabels":43,"otherNames":11},"DRUG","receiving aficamten","Aficamten will be administered at a specified dose according to each patient's tolerability, as assessed by echocardiography.",[34],[45],{"name":46,"role":47,"phone":48,"phoneExt":11,"email":49},"Xiaojie Xie, MD, PhD","CONTACT","86+571-87784700","xiexj@zju.edu.cn",{"type":51,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100657997","aficamten-and-patient-reported-outcomes-in-real-world-nhcm-100657997",false,"NCT07846176","Aficamten and Patient-Reported Outcomes in Real-World nHCM","Comprehensive Aficamten Management and Patient-reported Health Outcomes in Real-world nHCM","CAMPHOR-HCM","Inclusion Criteria:\n\n* Age 18-85 years.\n* Confirmed diagnosis of HCM:\n\n  1. Left ventricular wall thickness ≥15 mm at any site on echocardiography or cardiac magnetic resonance.\n  2. Left ventricular wall thickness ≥13 mm in individuals testing positive for a pathogenic variant or in genetically affected family members.\n  3. Ventricular wall thickening caused by other cardiovascular diseases or systemic or metabolic disorders has been excluded.\n* Symptomatic nHCM patients meeting all of the following conditions:\n\n  1. Left ventricular outflow tract gradient (LVOTG) \\\u003C30 mmHg at rest and\u002For with provocation.\n  2. Presence of any one of the following symptoms: fatigue (weakness), dyspnea, chest pain, palpitations, or syncope.\n  3. New York Heart Association (NYHA) functional class II or III.\n* Left ventricular ejection fraction (LVEF) ≥60% as assessed by transthoracic echocardiography.\n* Signed and dated written informed consent, and willingness to return for clinical follow-up.\n\nExclusion Criteria:\n\n* LVOTG ≥30 mmHg at rest and\u002For with provocation.\n* LVEF \\\u003C50% on transthoracic echocardiography.\n* Symptomatic hypotension or systolic blood pressure (SBP) \\\u003C100 mmHg.\n* Severe renal impairment, estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin\u002F1.73 m², or currently receiving blood purification therapy.\n* Planned implantable cardioverter-defibrillator (ICD) implantation or cardiac resynchronization therapy (CRT) within 3 months.\n* Women who are pregnant or planning to become pregnant during the trial.\n* Currently participating in another investigational device or drug trial.\n* Any other clinical condition with an expected survival of less than 2 years.","ALL","18 Years","85 Years",{"count":64,"type":65},100,"ESTIMATED","OBSERVATIONAL","This multicenter, prospective, observational, real-world clinical study aims to evaluate the efficacy and safety of Aficamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM) by prospectively observing changes in symptoms, biomarkers, imaging findings, and adverse reactions, etc. It will also record the dosing regimens at which individual patients achieve steady state, and explore the treatment patterns of Aficamten in Chinese patients with symptomatic nHCM.",[69],"Hypertrophic Cardiomyopathy (HCM)",[71,72],"non obstructive hypertrophic cardiomyopathy","aficamten","NOT_YET_RECRUITING","2026-09-23",{"date":76,"type":77},"2026-09-29","ACTUAL",{"date":79,"type":65},"2027-06-01",{"date":81,"type":65},"2029-12-01",{"name":5,"class":6}]